{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T12:26:14Z","timestamp":1791721574718,"version":"4.3.4"},"reference-count":96,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.ejca.2023.02.018","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T21:34:32Z","timestamp":1677792872000},"page":"178-215","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":160,"special_numbering":"C","title":["Management of patients with advanced prostate cancer\u2014metastatic and\/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022"],"prefix":"10.1016","volume":"185","author":[{"given":"Silke","family":"Gillessen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Bossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian D.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"de Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Fizazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas D.","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Mottet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Shore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Small","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Tombal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel S.","family":"Antonarakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana M.","family":"Aparicio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhardt","family":"Attard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz M.","family":"Beer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himisha","family":"Beltran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Bjartell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob G.","family":"Bristow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Bulbul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orazio","family":"Caffo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather H.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim N.","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline S.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gedske","family":"Daugaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"De Santis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Duran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Eeles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Efstathiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Efstathiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onyeanunam Ngozi","family":"Ekeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Fanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix Y.","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Fonteyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Fossati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Frydenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gleave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwenaelle","family":"Gravis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Halabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Heinrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celestia","family":"Higano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa G.","family":"Horvath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara A.","family":"Jereczek-Fossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindran","family":"Kanesvaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pirkko-Liisa","family":"Kellokumpu-Lehtinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja B.","family":"Khauli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Klotz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gero","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja","family":"Leibowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Logothetis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Mahal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Maluf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquin","family":"Mateo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Matheson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niven","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Merseburger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia K.","family":"Morgans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hind","family":"Mrabti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Mukherji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Declan G.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vedang","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul L.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William K.","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piet","family":"Ost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe M.","family":"O\u2019Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwar R.","family":"Padhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmel J.","family":"Pezaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren M.C.","family":"Poon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin C.","family":"Pritchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny M.","family":"Rabah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Rathkopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles J.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pablo","family":"Sade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Sartor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard I.","family":"Scher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nima","family":"Sharifi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwona","family":"Skoneczna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Soule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Spratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Srinivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cora N.","family":"Sternberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Steuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyoshi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Sydes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary-Ellen","family":"Taplin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derya","family":"Tilki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Levent","family":"T\u00fcrkeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Turco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroji","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotsugu","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y\u00fcksel","family":"\u00dcr\u00fcn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire L.","family":"Vale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge","family":"van Oort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Vapiwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Walz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosj","family":"Yamoah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingwei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan Y.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almudena","family":"Zapatero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Zilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelius","family":"Omlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejca.2023.02.018_bib1","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.eururo.2022.11.002","article-title":"Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-\/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022","volume":"83","author":"Gillessen","year":"2023","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.ejca.2023.02.018_bib2","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.eururo.2017.06.002","article-title":"Management\u00a0of patients with advanced prostate cancer: the report of the\u00a0Advanced Prostate Cancer Consensus Conference APCCC 2017","volume":"73","author":"Gillessen","year":"2018","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ejca.2023.02.018_bib3","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.eururo.2020.01.012","article-title":"Management\u00a0of patients with advanced prostate cancer: report of the Advanced Prostate\u00a0Cancer Consensus Conference 2019","volume":"77","author":"Gillessen","year":"2020","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ejca.2023.02.018_bib4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.eururo.2022.04.002","article-title":"Management\u00a0of patients with advanced prostate cancer: report from the Advanced Prostate\u00a0Cancer Consensus Conference 2021","volume":"82","author":"Gillessen","year":"2022","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.ejca.2023.02.018_bib5","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"issue":"Supplement 5","key":"10.1016\/j.ejca.2023.02.018_bib6","article-title":"Practice patterns in management of hormone sensitive metastatic and castrate-resistent non-metastatic prostate cancer","volume":"207","author":"Joyce","year":"2022","journal-title":"J\u00a0Urol"},{"issue":"10336","key":"10.1016\/j.ejca.2023.02.018_bib7","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u00a0\u00d7\u00a02 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ejca.2023.02.018_bib8","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"issue":"32","key":"10.1016\/j.ejca.2023.02.018_bib9","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2023.02.018_bib10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejca.2023.02.018_bib11","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","article-title":"Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial","volume":"14","author":"Gravis","year":"2013","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2023.02.018_bib12","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"issue":"10024","key":"10.1016\/j.ejca.2023.02.018_bib13","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2023.02.018_bib14","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejca.2019.04.031","article-title":"Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients","volume":"116","author":"Boyle","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.02.018_bib15","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer update","volume":"79","author":"Mottet","year":"2022","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.ejca.2023.02.018_bib16","doi-asserted-by":"crossref","first-page":"134","DOI":"10.6004\/jnccn.2021.0008","article-title":"NCCN guidelines insights: prostate cancer, version 1.2021","volume":"19","author":"Schaeffer","year":"2021","journal-title":"J Natl Compr Cancer Netw"},{"issue":"9","key":"10.1016\/j.ejca.2023.02.018_bib17","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2023.02.018_bib18","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.eururo.2018.11.045","article-title":"Compound genomic alterations of TP53, PTEN, and RB1 tumor suppressors in localized and metastatic prostate cancer","volume":"76","author":"Hamid","year":"2019","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.ejca.2023.02.018_bib19","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41391-021-00430-4","article-title":"Differential impact of tumor suppressor gene (TP53, PTEN, RB1) alterations and treatment outcomes in metastatic, hormone-sensitive prostate cancer","volume":"25","author":"Velez","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"9","key":"10.1016\/j.ejca.2023.02.018_bib20","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/pros.24135","article-title":"Genomic profiles and clinical outcomes in primary versus secondary metastatic hormone-sensitive prostate cancer","volume":"81","author":"Nizialek","year":"2021","journal-title":"Prostate"},{"issue":"2","key":"10.1016\/j.ejca.2023.02.018_bib21","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/pros.24269","article-title":"Clinical and genomic features of SPOP-mutant prostate cancer","volume":"82","author":"Nakazawa","year":"2022","journal-title":"Prostate."},{"issue":"5","key":"10.1016\/j.ejca.2023.02.018_bib22","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.eururo.2020.06.033","article-title":"Association of SPOP mutations with outcomes in men with de novo metastatic castration-sensitive prostate cancer","volume":"78","author":"Swami","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2023.02.018_bib23","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.urology.2020.08.028","article-title":"Germline HSD3B1 genetics and prostate cancer outcomes","volume":"145","author":"Thomas","year":"2020","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.ejca.2023.02.018_bib24","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.6496","article-title":"HSD3B1 genotype and clinical outcomes in metastatic castration-sensitive prostate cancer","volume":"6","author":"Hearn","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2023.02.018_bib25","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.urology.2020.12.021","article-title":"Prostate cancer foundation hormone-sensitive prostate cancer\u00a0biomarker working group meeting summary","volume":"155","author":"Hofmann","year":"2021","journal-title":"Urology"},{"key":"10.1016\/j.ejca.2023.02.018_bib26","article-title":"Radiographic progression in the absence of prostate-specific antigen (PSA) progression in patients with metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analysis of ARCHES","volume":"40","author":"Armstrong","year":"2022"},{"issue":"4","key":"10.1016\/j.ejca.2023.02.018_bib27","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S1470-2045(22)00092-4","volume":"23","author":"Dearnaley","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2023.02.018_bib28","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1200\/GO.20.00562","article-title":"Global access to radiotherapy-work in progress","volume":"7","author":"Gospodarowicz","year":"2021","journal-title":"JCO Glob Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2023.02.018_bib29","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S1470-2045(15)00222-3","article-title":"Expanding global access to radiotherapy","volume":"16","author":"Atun","year":"2015","journal-title":"Lancet Oncol"},{"issue":"10162","key":"10.1016\/j.ejca.2023.02.018_bib30","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2023.02.018_bib31","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1200\/GO.20.00518","article-title":"Consensus\u00a0on the screening, staging, treatment, and surveillance of localized, recurrent,\u00a0and metastatic prostate cancer: the first global prostate cancer consensusconference for developing countries","volume":"7","author":"Maluf","year":"2021","journal-title":"JCO Glob Oncol"},{"issue":"22","key":"10.1016\/j.ejca.2023.02.018_bib32","doi-asserted-by":"crossref","first-page":"4221","DOI":"10.1002\/cncr.33818","article-title":"Presentation, patterns of care, and outcomes of patients with prostate cancer in sub-Saharan Africa: a population-based registry study","volume":"127","author":"Seraphin","year":"2021","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2023.02.018_bib33","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4103\/0970-1591.174774","article-title":"Demography and disease characteristics of prostate cancer in India","volume":"32","author":"Hariharan","year":"2016","journal-title":"Indian J Urol"},{"issue":"16_suppl","key":"10.1016\/j.ejca.2023.02.018_bib34","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.5070","article-title":"Defining more precisely the effects of docetaxel plus ADT for men with mHSPC: meta-analysis of individual participant data from randomized trials","volume":"40","author":"Vale","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.02.018_bib35","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.urology.2016.10.044","article-title":"A pilot study of a multimodal treatment paradigm to accelerate drug evaluations in early-stage metastatic prostate cancer","volume":"102","author":"O'Shaughnessy","year":"2017","journal-title":"Urology"},{"issue":"7","key":"10.1016\/j.ejca.2023.02.018_bib36","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s12032-020-01385-7","article-title":"Multidisciplinary total eradication therapy (TET) in men with newly diagnosed oligometastatic prostate cancer","volume":"37","author":"Reyes","year":"2020","journal-title":"Med Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2023.02.018_bib37","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12032-022-01662-7","article-title":"Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer","volume":"39","author":"Reyes","year":"2022","journal-title":"Med Oncol"},{"issue":"1108","key":"10.1016\/j.ejca.2023.02.018_bib38","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20190353","article-title":"Prostate cancer with low burden skeletal disease at diagnosis: outcome of concomitant radiotherapy on primary tumor and metastases","volume":"93","author":"Deantoni","year":"2020","journal-title":"Br J Radiol"},{"issue":"1","key":"10.1016\/j.ejca.2023.02.018_bib39","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.eururo.2019.02.003","article-title":"Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: a STOPCAP systematic review and meta-analysis","volume":"76","author":"Burdett","year":"2019","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.ejca.2023.02.018_bib40","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.euo.2022.06.001","article-title":"Combination of androgen deprivation therapy with radical local therapy versus androgen deprivation therapy alone for newly diagnosed oligometastatic prostate cancer: a phase II randomized controlled trial","volume":"5","author":"Dai","year":"2022","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2023.02.018_bib41","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II Trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2023.02.018_bib42","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"issue":"10185","key":"10.1016\/j.ejca.2023.02.018_bib43","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ejca.2023.02.018_bib44","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.eururo.2018.06.004","article-title":"Stereotactic Abative Body Radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial","volume":"74","author":"Siva","year":"2018","journal-title":"Eur Urol"},{"issue":"29","key":"10.1016\/j.ejca.2023.02.018_bib45","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1200\/JCO.22.00644","article-title":"Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials","volume":"40","author":"Deek","year":"2022","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.ejca.2023.02.018_bib46","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.1007","article-title":"NRG-BR002: a\u00a0phase IIR\/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and\/or surgical resection (SR) for newly oligometastatic breast cancer","volume":"40","author":"Chmura","year":"2022","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2023.02.018_bib47","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1056\/NEJMoa2001342","article-title":"Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide","volume":"383","author":"Fizazi","year":"2020","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.ejca.2023.02.018_bib48","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1056\/NEJMoa2003892","article-title":"Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer","volume":"382","author":"Sternberg","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejca.2023.02.018_bib49","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.eururo.2020.08.011","article-title":"Apalutamide and overall survival in prostate cancer","volume":"79","author":"Smith","year":"2021","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.ejca.2023.02.018_bib50","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/S1470-2045(21)00334-X","article-title":"Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials","volume":"22","author":"Fallah","year":"2021","journal-title":"Lancet Oncol"},{"issue":"24","key":"10.1016\/j.ejca.2023.02.018_bib51","doi-asserted-by":"crossref","first-page":"7448","DOI":"10.1158\/1078-0432.CCR-19-1050","article-title":"Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer","volume":"25","author":"Fendler","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.ejca.2023.02.018_bib52","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/bco2.158","article-title":"Patterns of care for non-metastatic castration-resistant prostate cancer: a\u00a0population-based study","volume":"3","author":"Malone","year":"2022","journal-title":"BJUI Compass"},{"issue":"1","key":"10.1016\/j.ejca.2023.02.018_bib53","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2967\/jnumed.121.263262","article-title":"Appropriate use criteria for prostate-specific membrane antigen PET Imaging","volume":"63","author":"Jadvar","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ejca.2023.02.018_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.862995","article-title":"Oligoprogression in metastatic, castrate-resistant prostate cancer-prevalence and current clinical practice","volume":"12","author":"Patel","year":"2022","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2023.02.018_bib55","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/pros.24132","article-title":"Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone\/enzalutamide treatment","volume":"81","author":"Onal","year":"2021","journal-title":"Prostate"},{"issue":"1","key":"10.1016\/j.ejca.2023.02.018_bib56","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1186\/s12885-020-06853-x","article-title":"Metastasis-directed therapy in castration-refractory prostate cancer (MEDCARE): a non-randomized phase 2 trial","volume":"20","author":"Berghen","year":"2020","journal-title":"BMC Cancer"},{"issue":"12","key":"10.1016\/j.ejca.2023.02.018_bib57","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1007\/s00345-019-02717-7","article-title":"Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study","volume":"37","author":"Triggiani","year":"2019","journal-title":"World J Urol"},{"issue":"4","key":"10.1016\/j.ejca.2023.02.018_bib58","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.euo.2022.02.002","volume":"5","author":"Pan","year":"2022","journal-title":"Eur Urol Oncol"},{"issue":"24","key":"10.1016\/j.ejca.2023.02.018_bib59","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with olaparib in metastatic castration-resistant prostate cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N Engl J Med"},{"issue":"32","key":"10.1016\/j.ejca.2023.02.018_bib60","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1200\/JCO.20.01035","article-title":"Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration","volume":"38","author":"Abida","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2023.02.018_bib61","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200043","article-title":"Abiraterone and olaparib for metastatic castration-resistant prostatecancer","volume":"1","author":"Clarke","year":"2022","journal-title":"NEJM Evid"},{"issue":"6_suppl","key":"10.1016\/j.ejca.2023.02.018_bib62","volume":"40","author":"Chi","year":"2022","journal-title":"J Clin Oncol"},{"issue":"Supplement 7","key":"10.1016\/j.ejca.2023.02.018_bib63","first-page":"S1168","article-title":"Detection of mutations in homologous recombination repair (HRR) genes in tumour tissue (TT) and circulating tumour DNA (ctDNA) from patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) in the phase III PROpel trial","volume":"33","author":"Armstrong","year":"2022","journal-title":"Ann\u00a0Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2023.02.018_bib64","doi-asserted-by":"crossref","first-page":"410","DOI":"10.2967\/jnumed.121.262240","article-title":"177Lu-prostate-specific membrane antigen ligand after 223Ra treatment in men with bone-metastatic castration-resistant prostate cancer: real-world clinical experience [published correction appears in J Nucl Med. 2022 Jul;63(7):100-1000]","volume":"63","author":"Sartor","year":"2022","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1016\/j.ejca.2023.02.018_bib65","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1159\/000506693","article-title":"Docetaxel rechallenge in patients with metastatic prostate cancer: a comprehensive review","volume":"43","author":"Assi","year":"2020","journal-title":"Oncol Res Treat"},{"issue":"7","key":"10.1016\/j.ejca.2023.02.018_bib66","first-page":"1770","article-title":"Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate","volume":"173","author":"Wu","year":"2018","journal-title":"Cancer\u00a0Cell"},{"issue":"3","key":"10.1016\/j.ejca.2023.02.018_bib67","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.eururo.2019.09.036","article-title":"Clinical outcomes in cyclin-dependent kinase 12 mutant advanced prostate cancer","volume":"77","author":"Reimers","year":"2020","journal-title":"Eur Urol"},{"issue":"11","key":"10.1016\/j.ejca.2023.02.018_bib68","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMcibr1808772","article-title":"Cyclin-dependent kinase 12, immunity, and prostate cancer","volume":"379","author":"Antonarakis","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.02.018_bib69","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1200\/PO.19.00399","article-title":"CDK12-altered prostate cancer: clinical features and therapeutic outcomes to standard systemic therapies, poly (ADP-Ribose) polymerase inhibitors, and PD-1 inhibitors","volume":"4","author":"Antonarakis","year":"2020","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2023.02.018_bib70","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s40425-018-0341-y","article-title":"Microsatellite instability in prostate cancer by PCR or next-generation sequencing","volume":"6","author":"Hempelmann","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2023.02.018_bib71","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0233260","article-title":"Mismatch repair deficiency in metastatic prostate cancer: response to PD-1 blockade and standard therapies","volume":"15","author":"Graham","year":"2020","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ejca.2023.02.018_bib72","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001065","article-title":"Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA","volume":"8","author":"Barata","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2023.02.018_bib73","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.eururo.2018.10.009","article-title":"Clinical features and therapeutic outcomes in men with advanced prostate cancer and dna mismatch repair gene mutations","volume":"75","author":"Antonarakis","year":"2019","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.ejca.2023.02.018_bib74","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1002\/onco.13601","article-title":"Tumor frameshift mutation proportion predicts response to immunotherapy in mismatch repair-deficient prostate cancer","volume":"26","author":"Sena","year":"2021","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.ejca.2023.02.018_bib75","article-title":"Comparative effectiveness of immune checkpoint inhibitors vs chemotherapy by tumor mutational burden in metastatic castration-resistant prostate cancer [published correction appears in JAMA Netw Open. 2022 May 2;5(5):e2213901]","volume":"5","author":"Graf","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ejca.2023.02.018_bib76","article-title":"PARP inhibitor insensitivity to BRCA1\/2 monoallelic mutations in microsatellite instability-high cancers","volume":"6","author":"Sokol","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2023.02.018_bib77","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"issue":"10276","key":"10.1016\/j.ejca.2023.02.018_bib78","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ejca.2023.02.018_bib79","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/pcan.2016.71","article-title":"Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL","volume":"20","author":"Bryce","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"6","key":"10.1016\/j.ejca.2023.02.018_bib80","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.eururo.2020.08.025","article-title":"Prostate-specific antigen progression in enzalutamide-treated men with nonmetastatic castration-resistant prostate cancer: any rise in prostate-specific antigen may require closer monitoring","volume":"78","author":"Saad","year":"2020","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.ejca.2023.02.018_bib81","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2023.02.018_bib82","first-page":"1651","article-title":"Novel framework for treatment response evaluation using PSMA PET\/CT in patients with metastatic castration-resistant prostate cancer (recip 1.0): an international multicenter study","volume":"63","author":"Gafita","year":"2022","journal-title":"J Nucl Med"},{"issue":"8","key":"10.1016\/j.ejca.2023.02.018_bib83","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41585-022-00618-w","article-title":"The future of PSMA PET and WB MRI as next-generation imaging tools in prostate cancer","volume":"19","author":"Wang","year":"2022","journal-title":"Nat Rev Urol"},{"issue":"2","key":"10.1016\/j.ejca.2023.02.018_bib84","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00259-020-04934-4","article-title":"Consensus statements on PSMA PET\/CT response assessment criteria in prostate cancer","volume":"48","author":"Fanti","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.ejca.2023.02.018_bib85","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13550-019-0554-1","article-title":"[68Ga]Ga-PSMA-11 PET\/CT for monitoring response to treatment in metastatic prostate cancer: is there any added value over standard follow-up?","volume":"9","author":"Kuten","year":"2019","journal-title":"EJNMMI Res"},{"issue":"16_suppl","key":"10.1016\/j.ejca.2023.02.018_bib86","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.5002","article-title":"[68Ga]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [177Lu]Lu-PSMA-617 in patients with mCRPC: a\u00a0VISION substudy","volume":"40","author":"Kuo","year":"2022","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2023.02.018_bib87","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","article-title":"PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial","volume":"23","author":"Buteau","year":"2022","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2023.02.018_bib88","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1158\/1078-0432.CCR-13-3309","article-title":"Aggressive variants of castration-resistant prostate cancer","volume":"20","author":"Beltran","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.ejca.2023.02.018_bib89","doi-asserted-by":"crossref","first-page":"T51","DOI":"10.1530\/ERC-21-0002","article-title":"The heterogeneity of prostate cancers lacking AR activity will require diverse treatment approaches","volume":"28","author":"Labrecque","year":"2021","journal-title":"Endocr Relat Cancer"},{"issue":"6320","key":"10.1016\/j.ejca.2023.02.018_bib90","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.aah4307","article-title":"SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer","volume":"355","author":"Mu","year":"2017","journal-title":"Science"},{"issue":"6320","key":"10.1016\/j.ejca.2023.02.018_bib91","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1126\/science.aah4199","article-title":"Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance","volume":"355","author":"Ku","year":"2017","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.ejca.2023.02.018_bib92","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ccell.2017.09.003","article-title":"Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling","volume":"32","author":"Bluemn","year":"2017","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.ejca.2023.02.018_bib93","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S1470-2045(19)30408-5","article-title":"Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial [published correction appears in Lancet Oncol. 2020 Jan;21(1):e14]","volume":"20","author":"Corn","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2023.02.018_bib94","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejca.2021.09.036","article-title":"Lack\u00a0of consensus identifies important areas for future clinical research: Advanced\u00a0Prostate Cancer Consensus Conference (APCCC) 2019 findings","volume":"160","author":"Vogl","year":"2022","journal-title":"Eur J Cancer"},{"issue":"14","key":"10.1016\/j.ejca.2023.02.018_bib95","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1200\/JCO.21.02304","article-title":"Controlling the control arm in metastatic castration-resistant prostate cancer trials: best standard of care or the minimum standard of care?","volume":"40","author":"Van Wambeke","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2023.02.018_bib96","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.annonc.2022.03.272","article-title":"Clinical trials for metastatic castrate-resistant prostate cancer-who is looking after the control patients? Questions for the future","volume":"33","author":"Ardolino","year":"2022","journal-title":"Ann Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923001107?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923001107?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:40:49Z","timestamp":1760733649000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923001107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":96,"alternative-id":["S0959804923001107"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.02.018","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of patients with advanced prostate cancer\u2014metastatic and\/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.02.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}